SLNO Vivo Opportunity LLC sells $26.3M worth of shares
Mar 29, 2025, 4:33 AM
0.00%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
Vivo Opportunity LLC sold 400,000 shares of SLNO on 26 March at $65.80 per share, worth a total of $26.3M. They now own 5,891,851 SLNO shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
